DFree Raises Funds for Predictive Bladder Monitoring Device

DFree, a Japanese innovator in assistive technology, has initiated a capital raise targeting ¥10.08 million (approximately $67,000 USD) through equity crowdfunding on the FUNDINNO platform. This funding round, open until August 6th, aims to bolster the company's production capabilities and accelerate its global expansion strategy, including the pursuit of crucial medical device certifications.

The company's flagship product is a non-invasive wearable device that employs ultrasonic sensors and artificial intelligence to predict the optimal time for urination. By monitoring bladder fullness, DFree provides timely alerts, significantly reducing the reliance on scheduled toileting or absorbent products. This technology holds immense potential for improving the quality of life for individuals with incontinence and supporting caregivers in institutional and home settings.

DFree offers a diversified product suite catering to various needs. The 'HomeCare' model is designed for personal use, while 'Professional' versions are tailored for healthcare facilities. A particularly innovative offering is the 'DFree Slim,' a remarkably lightweight and discreet unit weighing just 20 grams. The company has also developed 'DFree Ben,' which extends its predictive capabilities to assist with defecation timing, further broadening its application scope in personal care and continence management.

The impact of DFree's technology is already evident in its widespread adoption. As of July, the device has been implemented in 383 medical and caregiving facilities across Japan. Preliminary results from these deployments are striking, reporting a 50% reduction in diaper expenses and a substantial decrease of 150 care hours per month dedicated to urination management. Furthermore, a pilot study involving children with disabilities demonstrated a dramatic improvement in their urination success rate, escalating from a baseline of 15.0% to an impressive 83.5%.

Beyond its current applications, DFree is actively safeguarding its intellectual property, holding 10 patents with an additional 6 pending applications. This robust IP portfolio underscores the company's commitment to innovation and its unique position in the rapidly growing assistive technology market. The global market for incontinence products alone is projected to reach significant figures in the coming years, driven by aging populations and increased awareness of quality-of-life solutions.

The capital infusion will be strategically allocated to enhance DFree's manufacturing and supply chain infrastructure, expand its market penetration, and strengthen its customer support network. A key objective is securing domestic and international medical device accreditations, which will unlock broader market access and solidify its credibility within the healthcare sector. This move positions DFree to capitalize on the increasing demand for smart health solutions that empower individuals and optimize care delivery.